Becton Dickinson and Co (NYSE:BDX) – Equities researchers at Piper Jaffray Companies dropped their Q1 2020 earnings estimates for Becton Dickinson and in a research note issued on Tuesday, November 5th. Piper Jaffray Companies analyst W. Quirk now expects that the medical instruments supplier will post earnings per share of $2.67 for the quarter, down from their prior forecast of $3.04. Piper Jaffray Companies currently has a “Overweight” rating and a $266.00 price target on the stock. Piper Jaffray Companies also issued estimates for Becton Dickinson and’s Q2 2020 earnings at $3.27 EPS, Q1 2021 earnings at $2.84 EPS, Q3 2021 earnings at $3.39 EPS, Q4 2021 earnings at $3.67 EPS and FY2021 earnings at $13.15 EPS.

A number of other analysts have also recently weighed in on BDX. ValuEngine cut shares of Becton Dickinson and from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Wells Fargo & Co cut their price objective on shares of Becton Dickinson and from $290.00 to $285.00 and set an “outperform” rating on the stock in a report on Wednesday. Finally, Morgan Stanley raised their price objective on shares of Becton Dickinson and from $250.00 to $261.00 and gave the stock an “equal weight” rating in a report on Tuesday, July 16th. Five investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company. Becton Dickinson and currently has a consensus rating of “Buy” and a consensus target price of $266.09.

BDX stock traded up $0.22 during midday trading on Friday, reaching $244.79. 1,491,912 shares of the company were exchanged, compared to its average volume of 1,173,922. The company has a debt-to-equity ratio of 0.85, a quick ratio of 0.67 and a current ratio of 1.19. Becton Dickinson and has a 1-year low of $208.62 and a 1-year high of $264.74. The stock’s 50-day simple moving average is $251.93 and its 200 day simple moving average is $246.89. The company has a market cap of $66.59 billion, a price-to-earnings ratio of 20.96, a price-to-earnings-growth ratio of 1.62 and a beta of 1.09.

Becton Dickinson and (NYSE:BDX) last released its quarterly earnings data on Tuesday, November 5th. The medical instruments supplier reported $3.31 earnings per share for the quarter, topping analysts’ consensus estimates of $3.30 by $0.01. Becton Dickinson and had a net margin of 6.84% and a return on equity of 15.51%. The company had revenue of $4.58 billion for the quarter, compared to analysts’ expectations of $4.57 billion. During the same quarter last year, the company earned $2.93 earnings per share. The firm’s revenue for the quarter was up 4.1% on a year-over-year basis.

In other news, EVP Alexandre Conroy sold 9,829 shares of the firm’s stock in a transaction that occurred on Thursday, August 29th. The shares were sold at an average price of $255.06, for a total transaction of $2,506,984.74. Following the transaction, the executive vice president now directly owns 16,535 shares in the company, valued at $4,217,417.10. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Vincent A. Forlenza sold 11,532 shares of the firm’s stock in a transaction that occurred on Friday, September 6th. The stock was sold at an average price of $260.38, for a total transaction of $3,002,702.16. Following the transaction, the chief executive officer now owns 218,671 shares in the company, valued at $56,937,554.98. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 32,174 shares of company stock worth $8,354,013. Insiders own 0.12% of the company’s stock.

Institutional investors and hedge funds have recently made changes to their positions in the company. Eagle Asset Management Inc. purchased a new position in shares of Becton Dickinson and during the second quarter worth approximately $2,062,000. GAM Holding AG grew its position in Becton Dickinson and by 56.4% in the 2nd quarter. GAM Holding AG now owns 48,870 shares of the medical instruments supplier’s stock valued at $12,316,000 after buying an additional 17,622 shares during the last quarter. CIBC Asset Management Inc grew its position in Becton Dickinson and by 0.5% in the 2nd quarter. CIBC Asset Management Inc now owns 53,480 shares of the medical instruments supplier’s stock valued at $13,477,000 after buying an additional 247 shares during the last quarter. Black Diamond Financial LLC purchased a new position in Becton Dickinson and in the 2nd quarter valued at $562,000. Finally, Findlay Park Partners LLP grew its position in Becton Dickinson and by 8.3% in the 2nd quarter. Findlay Park Partners LLP now owns 2,220,000 shares of the medical instruments supplier’s stock valued at $559,462,000 after buying an additional 170,000 shares during the last quarter. Institutional investors and hedge funds own 84.29% of the company’s stock.

Becton Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products worldwide. The company's BD Medical segment offers peripheral IV and advanced peripheral catheters, central lines, acute dialysis catheters, vascular care and preparation products, needle-free IV connectors and extensions sets, IV fluids, closed-system drug transfer devices, hazardous drug detection, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, sharps disposal systems; infusion pumps and dedicated disposables, medication compounding workflow systems, automated medication dispensing, automated supply management systems, medication inventory optimization and tracking systems; syringes, pen needles, and other products for diabetes care; and prefillable drug delivery systems.

Recommended Story: Range Trading

Earnings History and Estimates for Becton Dickinson and (NYSE:BDX)

Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.